bioAffinity Technologies Files 8-K on Director Changes
Ticker: BIAFW · Form: 8-K · Filed: Aug 23, 2024 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: BIAF
TL;DR
BIAF board shakeup and exec comp changes filed. Watch for new strategy.
AI Summary
On August 19, 2024, bioAffinity Technologies, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the election of new directors and updates to compensatory arrangements for certain officers, alongside financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- August 19, 2024 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and potential departures, but specific names of newly elected or departing directors are not detailed in the provided text.
Were there any changes to executive officer positions?
The filing mentions 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers,' suggesting potential changes, but specific details are not in the provided text.
What is the nature of the updates to compensatory arrangements?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, but the specific details of these arrangements are not provided in the excerpt.
What financial statements or exhibits were filed?
The filing lists 'Financial Statements and Exhibits' as an item, but the content of these statements and exhibits is not detailed in the provided text.
What is the primary business of bioAffinity Technologies, Inc.?
bioAffinity Technologies, Inc. is in the business of 'SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]'.
Filing Stats: 992 words · 4 min read · ~3 pages · Grade level 10.3 · Accepted 2024-08-23 17:15:20
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
- $10,000 — er and provides for a monthly salary of $10,000 plus expenses. A brief description of
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex10-1.htm (EX-10.1) — 20KB
- ex99-1.htm (EX-99.1) — 16KB
- ex10-1_001.jpg (GRAPHIC) — 3KB
- ex_001.jpg (GRAPHIC) — 39KB
- 0001493152-24-033762.txt ( ) — 387KB
- biaf-20240819.xsd (EX-101.SCH) — 4KB
- biaf-20240819_def.xml (EX-101.DEF) — 28KB
- biaf-20240819_lab.xml (EX-101.LAB) — 37KB
- biaf-20240819_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 7KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 23, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer